A comparison of 1-benzylpiperazine and methamphetamine in their acute effects on anxiety-related behavior of hooded rats

Pharmacology Biochemistry and Behavior

Volumn 92, Issue 2, 2009, Pages 243-250

  Herbert, Cherie E ^a   Hughes, Robert N ^a  

^a UNIVERSITY OF CANTERBURY   (New Zealand)

Author keywords

1 Benzylpiperazine; Anxiety; Hooded rats; Methamphetamine

Indexed keywords

1 BENZYLPIPERAZINE DERIVATIVE; METHAMPHETAMINE; SODIUM CHLORIDE;

ACUTE DRUG ADMINISTRATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; LIGHT DARK BOX TEST; LIGHT DARK CYCLE; LOCOMOTION; LOW DRUG DOSE; MALE; MAZE TEST; NEUROCHEMISTRY; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; RAT STRAIN; REARING; RISK ASSESSMENT; SEX DIFFERENCE; STEREOTYPY;

ANIMALS; ANXIETY; FEMALE; MALE; MAZE LEARNING; METHAMPHETAMINE; PIPERAZINES; RATS; STEREOTYPED BEHAVIOR;

RATTUS;

EID: 59649106344     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.12.003     Document Type: Article

References (54)

1. Aitchison L.K., and Hughes R.N. Treatment of adolescent rats with 1-benzylpiperazine: a preliminary study of subsequent behavioral effects. Neurotoxicol Teratol 28 (2006) 453-458
2. Alansari M., and Hamilton D. Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. NZ Med J (2005). http://www.nzma.org.nz/journal/119-1233/1959/ URL: http://www.nzma.org.nz/journal/119-1233/1959/
3. Archer J. Tests for emotionality in rats and mice: a review. Anim Behav 21 (1973) 205-235
4. Archer J. Rodent sex differences in emotional and related behavior. Behav Biol 14 (1975) 451-479
5. Balmelli C., Kupferschmidt H., Rentsch K., and Schneemann M. Tödliches Hirnödem nach Einnahme von Ecstasy und Benzylpiperazin. Dtsch Med Wochenschr 126 (2001) 809-811
6. Baumann M.H., Ayestas M.A., Sharpe L.G., Lewis D.B., Rice K.C., and Rothman R.B. Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR 12909 decanoate. J Pharmacol Exp Ther 301 (2002) 1190-1197
7. Baumann M.H., Clark R.D., Budzynski A.G., Partilla J.S., Blough B.E., and Rothman R.B. Effects of "legal X" piperazine analogs on dopamine and serotonin release in rat brain. Ann NY Acad Sci 1025 (2004) 189-197
8. Baumann M.H., Clark R.D., Budzynski A.G., Partilla J.S., Blough B.E., and Rothman R.B. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 30 (2005) 550-560
9. Belcher A.M., O'Dell S.J., and Marshall J.F. Impaired objection recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity. Neuropsychopharmacology 30 (2005) 2026-2034
10. Belzung C. Measuring rodent exploratory behaviour. In: Crusio W.E., and Gerlai R.T. (Eds). Handbook of molecular-genetic techniques for brain and behavior research (1999), Elsevier, Amsterdam 738-749
11. Berger B.D. Conditioning of food aversions by injections of psychoactive drugs. J Comp Physiol Psychol 81 (1972) 21-26
12. Bisagno V., Ferguson D., and Luine V.N. Short toxic methamphetamine schedule impairs object recognition task in male rats. Brain Res 940 (2002) 95-101
13. Bowden M. Non-traditional designer substances: a new category of psychoactives in New Zealand (2004). http://www.erowid.org/chemicals/bzp/bzp_info1.shtml URL: http://www.erowid.org/chemicals/bzp/bzp_info1.shtml
14. Brain P.F., and Marrow L. Rodent models of human neuroses and psychoses. In: Haug M., and Whale R.E. (Eds). Animal models of human emotion and cognition (1999), American Psychological Association, Washington 59-75
15. Brennan K., Johnstone A., Fitzmaurice P., Lea R., and Schenk S. Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA). Drug Alcohol Depen 88 (2007) 204-213
16. Brennan K.A., Lake B., Hely L.S., Jones K., Gittings D., Colussi-Mas J., et al. N-benzylpiperazine has characteristics of a drug of abuse. Behav Pharmacol 18 (2007) 785-790
17. Bye C., Munro-Faure A.D., Peck A.W., and Young P.A. A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 6 (1973) 163-169
18. Campbell H., Cline W., Evans M., Lloyd J., and Peck A.W. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 6 (1973) 170-176
19. Clemens K.J., McGregor I.S., Hunt G.E., and Cornish J.L. MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research. Drug Alcohol Rev 26 (2007) 9-15
20. Clemens K.J., van Nieuwenhuyzen P.S., Li K.M., Cornish J.L., Hunt G.E., and McGregor I.S. MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology 173 (2004) 318-325
21. Creese I., and Iversen S.E. The role of forebrain dopamine systems in amphetamine induced stereotyped behaviour in the rat. Psychopharmacologia 39 (1974) 345-357
22. Fantegrossi W.E., Winger G., Woods J.H., Woolverton W.L., and Coop A. Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depen 77 (2005) 161-168
23. Gee P., Richardson S., Woltersdorf W., and Moore G. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. NZ Med J (2005). http://www.nzma.org.nz/journal/118-1227/1784/ URL: http://www.nzma.org.nz/journal/118-1227/1784/
24. Graeff F.G. On serotonin and experimental anxiety. Psychopharmacology 163 (2002) 467-476
25. Hall C.S. Emotional behavior in the rat: I. Defecation and urination as measures of individual differences in emotionality. J Comp Psychol 18 (1934) 385-403
26. Hascoët M., Bourin M., and Dhonnchadha B.A. The mouse light-dark box paradigm: a review. Prog Neuropsychopharmacol Biol Psychiatry 25 (2001) 141-166
27. Hashimoto K., Maeda H., and Goromaru T. Effects of benzylpiperazine derivatives on the neurotoxicity of 3,4-methylenedioxymethamphetamine in rat brain. Brain Res 590 (1992) 341-344
28. Hayase T., Yamamoto Y., and Yamamoto K. Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. Behav Pharmacol 16 (2005) 395-404
29. Hughes R.N. A review of atropinic drug effects on exploratory choice behavior in laboratory rodents. Behav Neur Biol 34 (1982) 5-41
30. Hughes R.N. Neotic preferences in laboratory rodents: issues, assessment and substrates. Neurosci Biobehav Rev 31 (2007) 441-464
31. Hughes R.N. Sex does matter: comments on the prevalence of male-only investigations of drug effects on rodent behaviour. Behav Pharmacol 18 (2007) 583-589
32. Hughes R.N., and Greig A.M. Effects of caffeine, methamphetamine and methylphenidate on reactions to novelty and activity in rats. Neuropharmacology 15 (1976) 673-676
33. Johnstone A.C., Lea R.A., Brennan K.A., Schenk S., Kennedy M.A., and Fitzmaurice P.S. Benzylpiperazine: a drug of abuse?. J Psychopharmacol 21 (2007) 888-894
34. Karch S.B., Stephens B.G., and Ho C.H. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicological profiles. J Forensic Sci 44 (1999) 359-368
35. Meredith C.W., Jaffe C., Ang-Lee K., and Saxon A.J. Implications of chronic methamphetamine use: a literature review. Harvard Rev Psychiat 13 (2005) 141-154
36. Meririnne E., Kajos M., Kankaanpaa A., and Seppala T. Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats. Basic Clin Pharmacol Toxicol 98 (2006) 346-350
37. Misslin R., and Ropartz P. Effects of methamphetamine on novelty-seeking behaviour in mice. Psychopharmacology 75 (1981) 39-43
38. Nicholson T.C. Prevalence of use, epidemiology and toxicity of 'herbal party pills' among those presenting to the emergency department. Emerg Med Austral 18 (2006) 180-184
39. Oberlander C., Euvrard C., Dumont C., and Boissier J.R. Circling behaviour induced by dopamine releasers and/or uptake inhibitors during degeneration of the nigrostriatal pathway. Eur J Pharmacol 60 (1979) 163-170
40. Peters D.A.V., Anisman H., and Pappas B.A. Monoamines and aversively motivated behaviors. In: Anisman H., and Bignami G. (Eds). Psychopharmacology of aversively motivated behavior (1978), Plenum Press, New York 257-343
41. Rawson R.A., Gonzales R., and Brethren P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat 23 (2002) 145-150
42. Richards J., Bretz S.W., Johnson E.B., Turnipseed S.D., Brofeldt B.T., and Derlet R.W. Methamphetamine abuse and emergency department utilization. West J Med 170 (1999) 198-202
43. Sanchez C. 5-HT1A receptors play an important role in the modulation of behavior of rats in a two-compartment black and white box. Behav Pharmacol 129 (1996) 197-205
44. Schindler C.W., Bross J.G., and Thorndike E.B. Gender differences in the behavioural effects of methamphetamine. Eur J Pharmacol 442 (2002) 231-235
45. Shoblock J.R., Maisonneuve I.M., and Glick S.D. Differences between d-methamphetamine and d-amphetamine in rats: working memory, tolerance, and extinction. Psychopharmacology 170 (2003) 150-156
46. Sommers I., Baskin D., and Baskin-Sommers A. Methamphetamine use among young adults: Health and social consequences. Addict Behav 31 (2006) 1469-1476
47. Staack R.F. Piperazine designer drugs of abuse. Lancet 369 (2007) 1411-1413
48. STANZ. Submission of the Social Tonics Association of New Zealand to the Health Select Committee on the matter of Misuse of Drugs Amendment Bill (No. 3) (2005). http://www.stanz.org.nz/SOP%20Submission%20for%20STANZ%20%20%20Jan%2020052.pdf URL: http://www.stanz.org.nz/SOP%20Submission%20for%20STANZ%20%20%20Jan%2020052.pdf
49. Theron L., Jansen K., and Miles J. Benzylpiperizine-based party pills' impact on the Auckland City Hospital Emergency Department Overdose Database (2002-2004) compared with ecstasy (MDMA or methylene dioxymethamphetamine), gamma hydroxybutyrate (GHB), amphetamines, cocaine, and alcohol. NZ Med J (2007). http://www.nzma.org.nz/journal/120-1249/2416/ URL: http://www.nzma.org.nz/journal/120-1249/2416/
50. Vorhees C.V., Reed T.M., Morford L.L., Fukumura M., Wood S.L., Brown C.A., et al. Periadolescent rats (P41-50) exhibit increased susceptibility to d-methamphetamine-induced long-term spatial and sequential learning deficits compared to juvenile (P21-30 or P31-40) or adult rats (P51-60). Neurotoxicol Teratol 27 (2005) 117-134
51. White I.M., Doubles L., and Rebec G.V. Cocaine-induced activation of striatal neurons during focused stereotypy in rats. Brain Res 810 (1998) 146-152
52. Wikström M., Holmgren P., and Ahlner J. A2 (N-benzylpiperazine) a new drug of abuse in Sweden. J Anal Toxicol 28 (2004) 67-70
53. Wilkins C., Girling M., and Sweetsur P. The prevalence of use, dependency and harms of legal 'party pills' containing benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP) in New Zealand. J Subst Abuse 12 (2007) 213-224
54. Wood D.M., Dargan P.I., Button J., Holt D.W., Ovaska H., Ramsey J., et al. Collapse, reported seizure - and an unexpected pill. Lancet 369 (2007) 1490